Skip to main content
. 2023 Feb 16;13:2804. doi: 10.1038/s41598-023-28638-5

Table 2.

Comparison of characteristics between the survivors and non-survivors among the patients with idiopathic nonspecific interstitial pneumonia.

Demographic characteristics All patients (N = 126) P value
Survivors (n = 93) Non-survivors (n = 33)
Age, years 58.8 (± 11.1) 63.6 (± 10.3) 0.034
Female sex 49 (52.7%) 15 (45.5%) 0.475
Smoking history 0.945

 Ever smoker

 Never smoker

36 (38.7%)

57 (61.3%)

13 (39.4%)

20 (60.6%)

Comorbidity

 Diabetes

 Hypertension

23 (24.7%)

14 (15.1%)

9 (27.3%)

10 (30.4%)

0.773

0.055

Bronchoalveolar lavage

 WBC, cells/μL

 Neutrophil, %

 Lymphocyte, %

 Macrophage, %

180.0 (90.0–300.0)

8.0 (3.0–17.0)

11.0 (4.0–26.0)

69.0 (51.0–83.0)

140.0 (52.5–217.5)

7.0 (2.0–21.0)

10.0 (5.0–23.0)

70.0 (50.0–87.0)

0.203

0.845

0.899

0.969

Baseline pulmonary function test

 FVC, L

 FVC, % predicted

 DLCO, mL/min/mmHg

 DLCO, % predicted

2.68 (± 0.86)

79.5 (± 18.3)

13.6 (± 4.2)

70.5 (± 18.4)

2.17 (± 0.56)

67.9 (± 13.1)

10.4 (± 2.9)

58.4 (± 15.2)

0.002

0.001

 < 0.001

0.001

Laboratory findings
 WBC, cells/μL 7525 (± 2010) 8633 (± 2266) 0.010
 Monocyte counts, cells/µL 559.0 (± 188.0) 612.9 (± 194.7) 0.164
 CRP, mg/dl 1.0 (± 1.7) 1.6 (± 2.2) 0.097
Medical treatments
 Steroids, n 81 (87.1%) 32 (97.0%) 0.109
 Immunosuppressants*, n 19 (20.4%) 13 (39.4%) 0.032
Clinical course
 Relapse**, n 24 (25.8%) 16 (48.5%) 0.016
 Acute exacerbation, n 9 (9.7%) 12 (36.4%)  < 0.001

Data are expressed as the mean (± standard deviation), median (interquartile range), or counts (%).

FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide; WBC, white blood cells; CRP, C-reactive protein.

*Medication including azathioprine, mycophenolate mofetil, or tacrolimus.

**Deterioration of clinical course including lung function, symptoms, or radiologic findings and re-prescribed steroids with or without immunosuppressants.